Real-time SEC alerts Start Free →
Profitelligence
Exact Sciences Corp
EXAS MEDIUM Impact

Exact Sciences Corp

Exact Sciences Appoints New Board Member Leslie Trigg

| 8-K |Healthcare

Summary

On April 29, 2025, Exact Sciences Corporation appointed Leslie Trigg as a Class II member of the Board, succeeding Kathleen Sebelius who retired. Trigg, with over 25 years in healthcare and medical device leadership, notably served as CEO and Chair of Outset Medical. Her appointment was made to fill the vacancy created by Sebelius' retirement, which was not due to any disagreements with the company. Trigg will be compensated in accordance with the company's Non-Employee Director Compensation Policy.

Profitelligence Profitelligence Alerts

Get alerts for EXAS

Be first to know when Exact Sciences Corp files with the SEC.

Set Up Alerts →

Filing Categories

Board Member Appointed Board Member Departure

Advertisement

About Exact Sciences Corp

Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.

Exchange: NASDAQ Industry: Diagnostics & Research Company Website →

Official SEC Documents

EXAS
EXAS Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement